image_alt_text
10

Marina E. Emborg, MD, Ph.D.

AIMBE College of Fellows Class of 2022
For outstanding contributions in advancing new regenerative therapies through demonstrations in pre-clinical models in neurodegenerative diseases.

Delivery of stem cell therapy for Parkinson’s safe in primate trial

Via Parkinsons News Today | August 2, 2024

Transplant approach to delivering therapy feasible, study say

A transplant approach used to deliver ANPD001, an investigational stem cell therapy for Parkinson’s disease, to the brain was found to be safe and feasible in non-human primates.

Data from these preclinical studies supported developer Aspen Neuroscience’s successful application to U.S. regulators seeking to launch a first-in-human study of the experimental treatment. The Phase 1/2a ASPIRO trial (NCT06344026) trial, enrolling by invitation only, is now testing ANPD001 in people with moderate to severe Parkinson’s disease… Continue reading.

...

Study of ANPD001 Autologous Neuronal Cell Replacement Treatment Approach Published in Journal of Neurosurgery

Via PR Newswire | July 29, 2024

The Journal of Neurosurgery has published online a study by the Wisconsin National Primate Research Center at the University of Wisconsin, Madison regarding a novel cell transplantation approach being used for delivery of ANPD001, an autologous, dopaminergic neuronal cell replacement under investigation by Aspen Neuroscience as a potential treatment for Parkinson’s Disease.

The study by the Wisconsin National Primate Research Center demonstrated the safety and feasibility of the treatment approach for ANPD001 in non-human primates. Aspen is currently investigating ANPD001 in the ASPIRO trial, a first-in-human, open-label Phase 1/2a clinical trial in people with moderate to severe Parkinson’s disease… Continue reading.

...

Dr. Marina Emborg Elected to the 2022 Class of the AIMBE College of Fellows

Via AIMBE | February 18, 2022

WASHINGTON, D.C. — The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of Marina E. Emborg, MD, Ph.D., Professor, Medical Physics, University of Wisconsin–Madison to its College of Fellows. Dr. Emborg was nominated, reviewed, and elected by peers and members of the AIMBE College of Fellows for outstanding contributions in advancing new regenerative therapies through demonstrations in pre-clinical models in neurodegenerative diseases.

The College of Fellows is comprised of the top two percent of medical and biological engineers in the country. The most accomplished and distinguished engineering and medical school chairs, research directors, professors, innovators, and successful entrepreneurs comprise the College of Fellows. AIMBE Fellows are regularly recognized for their contributions in teaching, research, and innovation. AIMBE Fellows have been awarded the Nobel Prize, the Presidential Medal of Science and the Presidential Medal of Technology and Innovation, and many also are members of the National Academy of Engineering, National Academy of Medicine, and the National Academy of Sciences… Continue reading.

...